Omalirel 150mg Injection

Omalirel 150mg Injection contains omalizumab, a monoclonal antibody used primarily in the treatment of moderate to severe allergic asthma and chronic spontaneous urticaria (hives). It works by binding to immunoglobulin E (IgE), a protein involved in allergic responses, thereby preventing it from attaching to its receptors on mast cells and basophils. This action reduces the release of inflammatory mediators that cause asthma symptoms and allergic reactions, leading to improved control of the condition.

Uses:

• Treatment of moderate to severe allergic asthma in patients with a positive skin test or in vitro reactivity to perennial allergens.
• Management of chronic spontaneous urticaria in adults and adolescents who remain symptomatic despite antihistamine treatment.
• Potential use in other allergic conditions as directed by a healthcare provider.

Side Effects:

• Common side effects: injection site reactions (redness, swelling, itching), headache, and fatigue.
• Serious side effects: anaphylaxis, thrombocytopenia (low platelet count), and serious allergic reactions; patients should seek immediate medical attention if symptoms like difficulty breathing or swelling occur.

Key Features:

• Contains omalizumab, a targeted therapy for IgE-mediated conditions.
• Administered as a subcutaneous injection, typically every 2 to 4 weeks.
• Reduces the frequency and severity of asthma attacks and allergic reactions.
• Can improve overall quality of life for patients with chronic allergic conditions.

FAQ:

1. How does Omalirel 150mg Injection work?
   Omalirel binds to IgE, preventing it from interacting with receptors that trigger allergic responses, thus reducing asthma symptoms and allergic reactions.
2. Who should use Omalirel?
   It is indicated for patients with moderate to severe allergic asthma and chronic spontaneous urticaria who do not respond adequately to standard treatments.
3. What precautions should I take while using Omalirel?
   Inform your healthcare provider about any allergies, especially to injectable medications, and report any unusual symptoms immediately.

References:

1. Genentech, Inc. “Xolair (omalizumab) injection, for subcutaneous use.” U.S. Food and Drug Administration. [Revised on 2021 Dec; Accessed on 5 Nov 2024]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK545183/
2. European Medicines Agency (EMA). “Omalizumab (Omalirel) Product Information.” [Accessed on 5 Nov 2024]. Available from: https://www.ema.europa.eu/en/documents/product-information/xolair-epar-product-information_en.pdf